Clinical Trial Update: A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of PXL770 versus placebo in adults with nonalcoholic fatty liver disease (NAFLD). Results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• PXL770 (PXL770)

Snippet

Sponsor: Poxel SA | Conditions: Nonalcoholic Fatty Liver | Phase 2 | Status: COMPLETED | Results posted: 2021-10-28